

• 李水盛主任

今年上半年對本系而言大有「多事」之秋之慨。從1月14日之陳春雄老師榮退，繼以3月25日舉辦孫教授之追思紀念會，4月18日許照惠系友會見李校長而簽署建藥學館承諾書事件，而隨之而來之藥學系改制計畫-擬四年制、六年制雙軌並行，藥學館籌建規劃，與新成立之分子醫藥學程師資之遴聘，其間穿插著2月1日第41屆系友郭錦樺及8月1日本系第一位博士班畢業生沈雅敬老師之到聘、高純琇老師借調財團法人醫藥品查驗中心、第10屆系友之畢業四十週年與第20屆系友畢業三十週年返校活動（4月29日），林林總總，不一而足。

這些事情，有些代表著系的薪火相傳已階段性完成，即第一代之師資已由第二代以後之專才接棒。值得一書的事，林慧玲老師自8月1日起擔任藥劑部主任，開啟由臨床藥學專業師資擔任斯職之首例，爾後想必有一番新氣象。

自許系友承諾捐款蓋藥學大樓之後，9月9日在其積極運籌下成立臺大藥物科技發展基金會之雛型，預計在年底前能正式運作，以彙集並整合系友之力量，全力促成臺大藥學之夢—具充分發展空間之世界一流藥學院。此臺大藥學永續經營規劃及系友之熱心參與，已被校長譽為臺大前所未有之典範。期盼在眾志成河之前提下，群策群力，早日圓夢。

## 2006年傑出系友得獎人 —方森茂校友

49期

焦  
點  
人  
物

• Sen-Maw Fang, Ph.D.



Dr. Sen-Maw Fang graduated from the School of Pharmacy, National Taiwan University in 1959 (第三屆) and went on to receive M. S. and Ph.D. degrees from the College of Pharmacy, University of Illinois in 1968. He then post-doctorated at the Ben May Cancer Research Institute, University of Chicago and worked on areas of androgen receptors in rat prostate. The work culminated in the identification of testosterone conversion to dihydrotestosterone (DHT) in the nuclei of prostatic cells by 5-alpha reductase. DHT was found to be the active androgen in prostate and was implicated in prostatic hypertrophy and prostate cancer.

In 1971, he accepted a teaching job at both the Department of Pharmacy and the Department of Pharmacology at the College of Pharmacy, University of Utah. He continued to work on androgen receptors in human prostate through funding by National Cancer Institute. He also received NICHD funding to work on the pharmacokinetics of estrogen and progestins in the uterine horn of rats after IUD administration. Through a group project, he also studied the pharmacokinetics of norethindrone release from a poly glutamate polymer device after i.m. injection. He also received grants to work on the bioavailability and pharmacokinetics of minerals in rat intestines before and after the minerals were chelated with various ligands. He also served as consultant in chelated minerals for internal as well as cosmetic applications. During his tenure in the University of Utah, he taught both undergraduate and graduate courses in biopharmaceutics and pharmacokinetics in the College of Pharmacy and also participated in group lectures to Master degree students in the College of Nursing and the College of Medicine.

Dr. Fang left the academy in 1985 to pursue full time his entrepreneurship. He established AMT Labs in Salt Lake City, which is a raw material supplier to mostly nutritional food supplement industries. Besides chemical synthesis of chelated minerals, the company also make other ingredients which total more than 300 items. AMT also provide special formulations such as sustained release tablets, directly compressible granules, effervescent powders, energy drinks, high solubility mineral product, etc. The company has products marketed all over the world.

He is now semi-retired and spend his time mostly on erhu (Chinese Traditional Orchestra), singing (baritone soloist in the chorus) and tennis. He has established a foundation to help various charity activities in Salt Lake City and other areas. His most pleasure now is to horse around with his three young grand kids.

# 2006年傑出系友得獎人

## — 吳晉校友 —

台大藥刊

焦點人物

• Jinn Wu (吳晉), Ph.D.



Dr. Jinn Wu obtained his B.S. in Pharmacy and a M.S. in Pharmaceutical Chemistry from the School of Pharmacy, National Taiwan University in 1971 (第15屆) and 1975 (under the supervision of Professor Chung-Hsiung Chen), respectively. He earned a Ph.D. degree in Natural Products Chemistry and Medicinal Chemistry from the College of Pharmacy (under the supervision of Professors Jack L. Beal and Raymond Duskotch), The Ohio State University in 1979. He was a postdoctoral research associate in the areas of Biomedical Mass Spectrometry and drug metabolism at the Department of Pharmacology, College of Medicine, The Ohio State University from 1979 - 1980. Dr. Wu joined FMC Corporation in Princeton, New Jersey in 1980 and made numerous contributions in new product research and development in metabolism, bioanalytical chemistry, and environmental chemistry.

Dr. Jinn Wu established XenoBiotic Laboratories, Inc. (XBL) in 1987 in Plainsboro, New Jersey. This company is considered as one of the top GLP contract research laboratories in the USA with high reputation in in vitro/in vivo drug metabolism, pharmacokinetics, metabolite profiling, metabolite identification and clinical bioanalysis.

Dr. Wu is a member of the American Chemical Society (ACS), the American Society of Pharmacognosy (ASP), the International Society for the Study of Xenobiotics (ISSX), American Chinese Pharmaceutical Association (ACPA), Sino-American Pharmaceutical Association (SAPA) and a member of American Association of Pharmaceutical Scientists (AAPS). He has published 48 scientific papers.

Dr. Wu has been very active in public services. He was the Team Manager for NTU College of Medicine Soccer Team (1968-71) and won National Colleges of Medicine Championship in 1970. He has served as a consultant for NIH-NCI for national research grant proposal review, was a member of the Board of Directors at Ardent Pharmaceuticals, Inc., Vice Chairman and a member of the Board of Directors for Monte Jade Science & Technology Association (East Coast), President of ACPA and National Taiwan University School of Pharmacy Alumni Association – North America (NTUSPAA-NA) 2001-2003. He was the recipient of The Jack L. Beal Postbaccalaureate Award, College of Pharmacy, The Ohio State University, in 1994.



## 2006年傑出系友得獎人 — 陳美玲校友

49期

焦  
點  
人  
物

• Mei-Ling Chen, Ph.D.



Dr. Mei-Ling Chen is Associate Director, Office of Pharmaceutical Science, Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA). The super office provides oversight of scientific reviews, regulatory policies and research activities for the Office of Biotechnology Products, Office of Generic Drugs, Office of New Drug Quality Assessment, and Office of Testing and Research. Over the years, Dr. Chen has served as an adviser to the Bureau of Pharmaceutical Affairs, Department of Health, Executive Yuan, Taiwan, Republic of China. Since 2001, she has been recognized as a Fellow of the American Association of Pharmaceutical Scientists (AAPS), a professional scientific society of more than 12,000 members from academia, industry, government and other research institutes worldwide. She is on the Editorial Board of Clinical Pharmacokinetics, a co-editor of the book entitled “Clinical Trials of Drugs and Biopharmaceuticals”, a referee of several prestigious scientific journals, and the author or co-author of numerous review articles, book chapters, research papers and abstracts in the field of clinical pharmacology and biopharmaceutics.

Dr. Chen was born in Taiwan and received her B.S. in Pharmacy from the National Taiwan University (第18屆). She earned her Ph.D. in Pharmacokinetics and Biopharmaceutics from the University of Illinois at Chicago in 1982. Following a two-year postdoctoral training, Dr. Chen joined the FDA in 1984. She was honored as a regulatory expert in 1990 and advanced to Chief, Pharmacokinetics Evaluation Branch, Division of Biopharmaceutics, Office of Research Resources in 1994. Dr. Chen was promoted to Director, Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics in 1995, and Associate Director, Office of Pharmaceutical Science in 2000.

While in the FDA, Dr. Chen has been appointed as Co-Chair of the Complex Drug Substances Coordinating Committee, and Topic Lead of the Biopharmaceutics Coordinating Committee in CDER. She has also served as chairperson or co-chairperson of several working groups on highly controversial and/or important scientific issues. She is instrumental in the development of many FDA guidance and policy documents for pharmaceutical industry and FDA staff, in particular, on the topics related to bioavailability and bioequivalence. Dr. Chen has received numerous merit awards from the FDA.

As a scientific and regulatory expert, Dr. Chen has frequently been requested as a speaker or moderator at national and international meetings. From 2000 to 2005, she was elected to serve on the U.S. Pharmacopeia (USP) Expert Committee - Bioavailability and Nutrient Absorption. Additionally, she was on the USP Expert Panel - Active Complexes from 2003 to 2004 and on the USP Advisory Panel to the International Health Expert Committee in 2005.

## 2006年傑出系友得獎人 —黃秀美校友

台大藥刊

• Amy Huang



AmyHuang is Vice President and Area Director of GlaxoSmithKline. She is responsible for all commercial operations of GlaxoSmithKline in China and Hong Kong.

Ms Huang was born in Taiwan and earned her B.S. in Pharmacy at National Taiwan University (第19屆). From 1997 to 2005, Ms. Huang was the Managing Director for GlaxoSmithKline Taiwan. This followed her tenure as the Marketing Director for SmithKline Beecham from 1993 to 1997.

Between 1982 to 1993, Ms. Huang held various positions within SmithKline Beecham Pharmaceuticals, including Acting Sales Manager, Product Manager, Medical and Clinical Research Manager, Marketing Manager, and Business Development Director (Taiwan & China). Prior to this, Ms. Huang played various roles from sales training, product regulatory to product management for a local pharmaceutical company, Su-Chiang & Co. Ltd. (The sole agent for SK&F) from 1976 to 1982, after graduating with a degree in Pharmacy from the National Taiwan University.

Ms. Huang is an active member of many industry associations. She most recently served as Co-Chair for the Pharmaceutical Committee of European Chamber of Commerce Taipei (ECCT), and Chaired the Communications Committee of Taiwan's International Research-Based Pharmaceutical Manufacturers Association (IRPMA). She was a Board member of the Taiwan Pharmaceutical Marketing & Management Association (TPMMA), and a Director for the IRPMA and the Taiwan Product Quality Research Institute (TPQRI). She was a member of both the American Chamber of Commerce in Taiwan and the British Chamber of Commerce in Taipei. Now she is one of the EC RDPAC in China.

Ms. Huang is an inspirational leader and successful executive. Her numerous awards and achievements include Outstanding Pharmaceutical Manager (Taiwan) and GSK's Inspirational Leadership Award (2005). Since the merger of Glaxo Wellcome and SmithKline Beecham in 2001, she presided over record country performance during a turbulent period of regulation. During her tenure as Managing Director of SmithKline Beecham Taiwan, she oversaw the launches of Engerix B, Tagmet, Augmentin, Avandia and Seretide etc., the most successful blockbusters in Taiwan Pharmaceutical industry history.

GSK is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that help people around the world do more, feel better and live longer.